The effects of GCSF primary prophylaxis on survival outcomes and toxicity in patients with advanced non-small cell lung cancer on first-line chemoimmunotherapy: a sub-analysis of the Spinnaker study
Name:
36675262.pdf
Size:
658.2Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Anpalakhan, S.Huddar, Prerana
Behrouzi, Roya
Signori, A.
Cave, J.
Comins, C.
Cortellini, A.
Addeo, A.
Escriu, C.
McKenzie, H.
Barone, G.
Murray, L.
Bhatnagar, G.
Pinato, D. J.
Ottensmeier, C.
Gomes, Fabio
Banna, G. L.
Affiliation
Portsmouth Hospitals University NHS Trust, Portsmouth PO6 3LY, UKIssue Date
2023
Metadata
Show full item recordCitation
Anpalakhan S, Huddar P, Behrouzi R, Signori A, Cave J, Comins C, et al. The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study. International journal of molecular sciences. 2023 Jan 16;24(2). PubMed PMID: 36675262. Pubmed Central PMCID: PMC9867035. Epub 2023/01/22. eng.Journal
International Journal of Molecular SciencesDOI
10.3390/ijms24021746PubMed ID
36675262Additional Links
https://dx.doi.org/10.3390/ijms24021746Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.3390/ijms24021746
Scopus Count
Collections
Related articles
- Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis.
- Authors: Anpalakhan S, Huddar P, Behrouzi R, Signori A, Cave J, Comins C, Cortellini A, Addeo A, Escriu C, McKenzie H, Barone G, Murray L, Pinato DJ, Ottensmeier C, Campos S, Muthuramalingam S, Chan S, Gomes F, Banna GL
- Issue date: 2023
- Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
- Authors: Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L
- Issue date: 2019 Aug
- [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
- Authors: Zhu WJ, Zhu HH, Liu YT, Lin L, Xing PY, Hao XZ, Cong MH, Wang HY, Wang Y, Li JL, Feng Y, Hu XS
- Issue date: 2022 May 23
- Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
- Authors: Peng L, Wang Y, Liu F, Qiu X, Zhang X, Fang C, Qian X, Li Y
- Issue date: 2020 Sep
- Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
- Authors: Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, Boucekine M, Mascaux C, Barlesi F
- Issue date: 2019 May